Evaluation of Renal Angioplasty on Atherosclerotic Stenosis Since 2010

Overview

The interest of renal angioplasty in the nosological framework of atherosclerotic stenosis has been significantly challenged by STAR and ASTRAL clinical trials in 2009, confirmed by the CORAL study in 2014. These studies did not show any benefit of the gesture on renal function, morbidity and cardiovascular mortality or the tension control. The aim of the study is to evaluate renal angioplasty on atherosclerotic stenosis.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 12, 2017

Detailed Description

Previous studies did not concern the indication of renal angioplasty in some high-risk situations, such as malignant or resistant renal vascular hypertension, OAP (Acute pulmonary oedema) flash or acute renal failure of ischemic origin. There is no work in the literature that has studied retrospectively the evolution of angioplasty practices renal artery disease on atherosclerotic stenosis since 2009, nor their remote results of the gesture.

Interventions

  • Procedure: Renal artery angioplasty
    • Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin : Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital Identification of prognostic factors

Clinical Trial Outcome Measures

Primary Measures

  • Composite endpoint at 3 years
    • Time Frame: The inclusion day
    • Composite endpoint at 3 years : Cardiovascular or renal mortality, Initiation of a renal replacement therapy or estimated glomerular filtration rate decrease of more than 50%, Cardiovascular morbidity: hospitalization for congestive heart failure, myocardial infarction, myocardium, stroke.

Participating in This Clinical Trial

Inclusion Criteria

  • OAP flash: hospitalization for Acute congestive heart failure without any other identified etiology than renal artery stenosis – Resistant arterial hypertension under treatment including a diuretic – Acute renal failure or ischemic renal failure quickly progressive – Radiological criteria: renal ischemia visualized at arterial time of angio-CT or renal angio-MRI Exclusion Criteria:

  • Renal transplant patients – Patients with another etiology of secondary hypertension, including fibro-muscular dysplasia of renal artery – Restenosis on stent, angioplasty of accessory renal artery – Patients subject to legal protection (safeguard of justice, guardianship) and persons deprived of liberty – Patients objecting to participate to the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rennes University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Thierry FROUGET, Principal Investigator, CHU Rennes

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.